Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Arcturus Therapeutics, with a focus on how actual results compare to estimates, which could significantly impact stock price [1] Financial Expectations - Arcturus Therapeutics is expected to report a quarterly loss of $1.17 per share, reflecting a year-over-year change of -233% [2] - Revenues are projected to be $22.12 million, down 72.5% from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised 109.3% lower in the last 30 days, indicating a bearish sentiment among analysts [2] - The Most Accurate Estimate for Arcturus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.43% [5] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with predictive power being significant for positive readings only [3][4] - Arcturus currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [6] Historical Performance - In the last reported quarter, Arcturus was expected to post a loss of $1.69 per share but actually reported a loss of $0.32, resulting in a surprise of +81.07% [7] - Over the past four quarters, the company has beaten consensus EPS estimates two times [7] Conclusion - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [8] - Arcturus Therapeutics does not appear to be a compelling earnings-beat candidate, and investors should consider additional factors before making decisions [8]